ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0434

The advantage of a “tight control” and “treat-to-target” strategy in new-onset rheumatoid arthritis patients in daily rheumatology practice

Katarina Friberger Pajalic1, Jon Einarsson1, Caroline Bengtsson2, Elisabeth Mogard3, Ellen Landgren4, Carmen Roseman3, Elisabet Lindqvist3, Johan Karlsson Wallman5, Tor Olofsson6 and Meliha Kapetanovic3, 1Lunds University, Department of clinical sciences, section of Rheumatology Malmö and Skåne University Hospital Malmö, Sweden, Lund, Sweden, 2Skåne University Hospital Lund, Sweden, Lund, Sweden, 3Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, 4Lunds University, Department of clinical sciences, section of Rheumatology, Lund, Skane Lan, Sweden, 5Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Skane Lan, Sweden, 6Lunds University, Department of clinical sciences, section of Rheumatology, Lund, Sweden

Meeting: ACR Convergence 2025

Keywords: Outcome measures, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Since 2021, patients with new-onset rheumatoid arthritis (RA) at the Department of Rheumatology, Skåne University Hospital, Lund, Sweden, are invited to participate in a ”tight control” and ”treat-to-target” (TC+T2T) follow-up strategy (TINDRA study). This strategy includes follow-up visits to a rheumatologist (at diagnosis and 3, 6, 12, 18, 24 months) and rheumatology nurse-led physical/telephone consultations between physician visits every other week for 3 months and thereafter when needed. Visits include disease activity assessments and adjustment of anti-rheumatic treatment when needed, aiming for remission. The aim of the current study was to explore possible advantages of implementing this TC+T2T strategy over routine clinical practice in new-onset RA patients regarding achievement of remission (DAS28 < 2,6, DAS28CRP < 2,4, CDAI≤2,8, and remission defined as 0 swollen joints in the 28-joint count score [“0 swollen joints of 28” remission]).

Methods: RA patients with symptom duration < 12 months at diagnosis were eligible. Data on disease-, treatment characteristics and outcome measures for patients included in the TINDRA study and controls were retrieved from the Swedish Rheumatology Quality register (SRQ). Controls comprised early RA patients followed according to routine clinical practice at the rheumatology out-patient clinics elsewhere in the Skåne region during the same period. In total, 103 patients were followed according to the TC+T2T strategy and 740 according to routine care. Achievement of remission at 1 year after diagnosis was compared between the two strategies using logistic regression, adjusted for sex, age, symptom duration, number of swollen and tender joints, CRP, ACPA status and HAQ at diagnosis.

Results: Disease and treatment characteristics at diagnosis are summarized in Table1. Percentage females/mean age/mean symptom duration at inclusion were 73%/58 years/5,9 months (TC+T2T) and 69%/60 years/5,7 months (routine care).Figure 1 illustrates proportion (%) of patients reaching remission (green area) according to the “0 swollen joints of 28” definition at different follow-up times in patients and controls. Percentages of patients reaching DAS28, DAS28CRP and CDAI remission criteria increased in both groups over time, but the differences between the TC+T2T strategy and routine care were not significant. However, at 12 months of follow-up, the TC+T2T strategi was associated with significantly higher odds of reaching “0 swollen joints of 28” remission compared to routine care (Table2).

Conclusion: Compared to routine rheumatology care, the “tight control” and ”treat-to-target” follow-up strategy resulted in larger proportions of patients reaching remission throughout the first two years after RA diagnosis and a more than doubled probability of reaching the strict target of “no swollen joints” one year following the diagnosis. These findings suggest that such a strategy should be considered for implementation in routine care of patients with new-onset RA.

Supporting image 1Table 1. Disease and treatment characteristics at diagnosis

Supporting image 2Figure. illustrates proportion (%) of patients reaching remission (green area) according to the “0 swollen joints of 28” definition at different follow-up times in patients and controls.

Supporting image 3Table2. Predictors of achieving remission according to the “0 swollen joints of 28” definition, at 12 months of follow-up


Disclosures: K. Friberger Pajalic: None; J. Einarsson: None; C. Bengtsson: None; E. Mogard: AbbVie/Abbott, 6; E. Landgren: None; C. Roseman: None; E. Lindqvist: None; J. Karlsson Wallman: AbbVie/Abbott, 5, Amgen, 5, Eli Lilly, 5, Novartis, 5, Pfizer, 5; T. Olofsson: None; M. Kapetanovic: GlaxoSmithKlein(GSK), 6, UCB, 6.

To cite this abstract in AMA style:

Friberger Pajalic K, Einarsson J, Bengtsson C, Mogard E, Landgren E, Roseman C, Lindqvist E, Karlsson Wallman J, Olofsson T, Kapetanovic M. The advantage of a “tight control” and “treat-to-target” strategy in new-onset rheumatoid arthritis patients in daily rheumatology practice [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-advantage-of-a-tight-control-and-treat-to-target-strategy-in-new-onset-rheumatoid-arthritis-patients-in-daily-rheumatology-practice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-advantage-of-a-tight-control-and-treat-to-target-strategy-in-new-onset-rheumatoid-arthritis-patients-in-daily-rheumatology-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology